ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
about
Skeletal myosin light chain kinase regulates skeletal myogenesis by phosphorylation of MEF2CStructural mechanism for the specific assembly and activation of the extracellular signal regulated kinase 5 (ERK5) moduleMultiple signaling pathways regulate the transcriptional activity of the orphan nuclear receptor NURR1p38α MAP Kinase C-Terminal Domain Binding Pocket Characterized by Crystallographic and Computational AnalysesComputational prediction and experimental verification of new MAP kinase docking sites and substrates including Gli transcription factorsNovel roles for ERK5 and cofilin as critical mediators linking ERα-driven transcription, actin reorganization, and invasiveness in breast cancer.Disruption of chaperone-mediated autophagy-dependent degradation of MEF2A by oxidative stress-induced lysosome destabilization.Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.Molecular cloning and in silico analysis of the duck (Anas platyrhynchos) MEF2A gene cDNA and its expression profile in muscle tissues during fetal development.Unique MAP Kinase binding sitesBasal and IGF-I-dependent regulation of potassium channels by MAP kinases and PI3-kinase during eccentric cardiac hypertrophy.Modulation of lysine methylation in myocyte enhancer factor 2 during skeletal muscle cell differentiation.Cytoskeletal protein kinases: titin and its relations in mechanosensing.A p38α-selective chemosensor for use in unfractionated cell lysates.The role of ERK5 in T-cell signalling.MEF2 transcription factors in human placenta and involvement in cytotrophoblast invasion and differentiation.
P2860
Q24301871-86467A93-63E9-4442-AACE-00E9DC489B4AQ24600375-AE78592D-C5F0-4BF9-B844-CF94367002C0Q24672749-87E620E8-2775-4AE0-9357-4980831A20ACQ27655779-67C78AC6-D0A8-48BF-9166-C8554CA3C27CQ28475319-562F4E52-FE8C-48EB-9BD4-F80DD2F36AD0Q33610918-7B81CE07-46E6-4782-8353-869409A913D1Q33878919-232244E6-A884-4086-8E9D-AFEF17AF9A68Q35221333-501D8464-5314-48B5-AE2A-3BB7EB5428F4Q35855413-628A3E91-38A5-4C9E-B6B1-7DB256DFF152Q36494279-D278151C-8960-4E07-91BC-4C0BB522B27BQ37038968-06DDBDB0-007A-467E-B414-62054C4C45CAQ37417041-8DB9930F-83C5-45AF-B004-2B9AFEE1A314Q37854510-42B8EC55-9989-4E09-908F-EE9A29487273Q39655274-5F723A47-585E-4654-A0BB-A3A8FB466F32Q46826626-55EDEAAA-0915-4ABC-B883-0AA5B3D7A7EDQ48323428-45F404BF-D512-4851-9010-EC6969303E96
P2860
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@ast
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en-gb
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@nl
type
label
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@ast
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en-gb
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@nl
prefLabel
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@ast
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en-gb
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@nl
P2093
P2860
P921
P356
P1433
P1476
ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif
@en
P2093
Alex Galanis
Andrew D Sharrocks
Anne Clancy
P2860
P356
10.1042/BJ20031940
P407
P577
2004-08-01T00:00:00Z